Vidara Therapeutics
Vidara Therapeutics is a privately held biopharmaceutical company, founded in 2003 and headquartered between Dublin, Ireland and Roswell, United States. It operates with 501-1000 employees under a CSO/CFO/CMO leadership team and was the subject of a $660 million sale transaction.
- Company typePrivate
- Founded2003
- HeadquartersRoswell, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vidara Therapeutics does
Vidara Therapeutics is a privately held biopharmaceutical company with reported operations in Dublin, Ireland and Roswell, United States, and a headcount in the 501-1000 employee range. The company was incorporated in 2003 and is referenced through its corporate website domain vidararx.com, signaling a prescription pharmaceutical orientation. Its leadership team includes a Chief Scientific Officer (John Devane), Chief Financial Officer (David Kelly), and Chief Medical Officer / Chief Compliance Officer (Virinder Nohira), consistent with a mid-sized drug development organization with regulatory and compliance obligations.
The company's strategic activity in the source material is limited to two documented transactions: the acquisition of AGI Therapeutics in March 2014 for an undisclosed amount, and a $660 million sale of Vidara itself, the latter referenced only obliquely through a Humacyte press release describing a prior career transaction by corporate development executive Rick McElheny. A $2.3 million funding round is also recorded in July 2018. No specific therapeutic areas, product names, pipeline assets, marketed drugs, revenue figures, or geographic markets served are disclosed in the available source material, and the operating status is reported as "acquired" with the acquiring entity unnamed.
Vidara Therapeutics firmographics
Firmographics- Name
- Vidara Therapeutics
- Legal name
- Vidara Therapeutics
- Website
- https://vidararx.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Vidara Therapeutics is a privately held biopharmaceutical company, founded in 2003 and headquartered between Dublin, Ireland and Roswell, United States. It operates with 501-1000 employees under a CSO/CFO/CMO leadership team and was the subject of a $660 million sale transaction.
- Ownership category
- akta.pro rank
Vidara Therapeutics industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
Keywords
Where Vidara Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Roswell
- HQ country
- United States
- HQ region
- North America
Markets served
Vidara Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Vidara Therapeutics product offering
Product offeringCore offering
Vidara Therapeutics was a privately held biopharmaceutical company that developed and commercialized specialty pharmaceutical products, growing in part through corporate acquisitions such as AGI Therapeutics (acquired March 2014). The company operated with 501–1,000 employees across Ireland and the United States and was ultimately sold in a $660 million corporate transaction. Specific therapeutic franchises, product names, and pipeline assets are not disclosed in the available source material.
Product overview
No information available about Vidara Therapeutics' products or services in the provided sources. The only reference to Vidara Therapeutics is in a news article noting that it was the subject of a $660 million sale transaction led by Rick McElheny prior to his appointment at Humacyte.
Differentiator
Problem solved
Functional benefit
Companies that use Vidara Therapeutics
Customer profileIdeal customer profiles1 record
Vidara Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Vidara Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights2 records
Vidara Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Perrigo Company: Ireland-domiciled pharma with a broad specialty and consumer health portfolio; comparable in corporate footprint (Ireland) and as a larger incumbent in the same specialty distribution space.
- Lundbeck: Specialty pharma focused on neurology and rare diseases, comparable as a branded specialty player with a European heritage and US commercial operations.
Direct peers
- Endo International: Specialty and branded pharmaceuticals company with a portfolio approach in GI, pain, and specialty endocrinology, overlapping with the AGI Therapeutics GI focus area.
- Jazz Pharmaceuticals: Ireland-domiciled specialty pharma with a US operational base, focused on branded specialty and rare disease therapeutics, mirroring Vidara's structural and strategic profile.
- Bausch Health: Large branded specialty pharma operator with a long M&A roll-up track record and a GI-focused commercial franchise historically tied to specialty care assets comparable to AGI Therapeutics.
- Shire: Ireland-domiciled specialty pharma that built value through targeted M&A and rare/specialty disease focus; directly comparable to Vidara's Ireland-based, M&A-driven specialty pharma model.
- Mallinckrodt: Branded specialty pharmaceuticals company with a similar specialty care portfolio strategy and history of corporate development transactions in the same valuation tier.
- Horizon Therapeutics: Ireland-domiciled, US-operating specialty and rare disease pharma built through aggressive M&A; analogous to Vidara in structure, strategy, and exit-value scale.
- Recordati: European specialty pharma with a strong US presence and focus on rare and specialty diseases, comparable to Vidara's cross-Atlantic specialty care model.
Emerging players
- Ardelyx: Smaller specialty GI-focused biopharma; relevant given Vidara's acquisition of AGI Therapeutics and the GI specialty adjacency, though at a much smaller scale.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
Vidara Therapeutics social profiles
Digital presenceVidara Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vidara Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Vidara Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vidara Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vidara Therapeutics
What does Vidara Therapeutics do?
Vidara Therapeutics was a privately held biopharmaceutical company that developed and commercialized specialty pharmaceutical products, growing in part through corporate acquisitions such as AGI Therapeutics (acquired March 2014). The company operated with 501–1,000 employees across Ireland and the United States and was ultimately sold in a $660 million corporate transaction. Specific therapeutic franchises, product names, and pipeline assets are not disclosed in the available source material.
Is Vidara Therapeutics a public or private company?
Vidara Therapeutics is a private company. It is classified as unknown and is currently acquired.
When was Vidara Therapeutics founded?
Vidara Therapeutics was founded in 2003. It employs 501 to 1,000 people.
Where is Vidara Therapeutics based?
Vidara Therapeutics is headquartered in Roswell, United States, in the North America region.
Who are Vidara Therapeutics's main competitors?
Broad incumbents on record are Perrigo Company and Lundbeck. Direct peers are Endo International, Jazz Pharmaceuticals, Bausch Health, Shire, Mallinckrodt, Horizon Therapeutics and Recordati. Ardelyx is listed as an emerging player.
Does Vidara Therapeutics have an API?
No public API is recorded for Vidara Therapeutics.
What industry is Vidara Therapeutics in?
Vidara Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.